Get to know our clinical trials
Phase IA/IB, open-label, multicenter clinical trial of IGM-8444 in patients with relapsed, refractory or newly diagnosed cancer.
THE OBJECTIVE OF THIS STUDY IS TO ANALYZE THE SAFETY OF IGM-8444 TOGETHER WITH STANDARD TREATMENT, COMPARED TO STANDARD TREATMENT IN PATIENTS WITH COLORECTAL CANCER, AND TO UNDERSTAND HOW THEIR BODY PROCESSES IGM-8444
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE IA/IB, OPEN-LABEL, MULTICENTER STUDY OF IGM-8444 IN MONOTHERAPY AND IN COMBINATION IN PATIENTS WITH RELAPSED, REFRACTORY OR NEWLY DIAGNOSED CANCER
- Code EudraCT: 023-504545-31-00
- Protocol number: IGM-8444-001
- Promoter: IGM Biosciences, Inc.
- Molecule/Drug: IGM-8444
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.